Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries

Analytical Biochemistry

Volumn 434, Issue 1, 2013, Pages 105-111

  Morisseau, Christophe ^a   Sahdeo, Sunil ^b   Cortopassi, Gino ^b   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ebselen; HTS assay; Phosphatase; Soluble epoxide hydrolase

Indexed keywords

BLOOD PRESSURE; CELL PROLIFERATION; DIAGNOSIS; DISEASE CONTROL; DRUG DELIVERY; HYDROLASES; PETROLEUM RESERVOIR EVALUATION;

ARACHIDONIC ACIDS; CARDIO-VASCULAR DISEASE; CLINICAL EVALUATION; EBSELEN; ENVIRONMENTAL TOXINS; EPOXIDE HYDROLASES; N-TERMINAL DOMAINS; PHOSPHATASE ACTIVITY;

PHOSPHATASES;

EBSELEN; EPHX2 PHOSPHATASE; PHOSPHATASE; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DISSOCIATION CONSTANT; ENZYME ACTIVITY; ENZYME DENATURATION; ENZYME INHIBITOR COMPLEX; HYDROLYSIS; IC 50; INCUBATION TIME; MICELLE; MOLECULAR LIBRARY; PRIORITY JOURNAL; SCREENING TEST; SIGNAL NOISE RATIO;

PHOS;

EID: 84871977397     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2012.11.017     Document Type: Article

References (40)

1. J.W. Newman, C. Morisseau, and B.D. Hammock Epoxide hydrolases: their roles and interactions with lipid metabolism Prog. Lipid Res. 44 2005 1 51
2. C. Morisseau, and B.D. Hammock Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical Pest Manage. Sci. 64 2008 594 609
3. B.M. De Taeye, C. Morisseau, J. Coyle, J.W. Covington, A. Luria, J. Yang, S.B. Murphy, D.B. Friedman, B.D. Hammock, and D.E. Vaughan Expression and regulation of soluble epoxide hydrolase in adipose tissue Obesity 18 2010 489 498
4. G.A. Gomez, C. Morisseau, B.D. Hammock, and D.W. Christianson Structure of human soluble epoxide hydrolase reveals mechanistic interferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis Biochemistry 43 2004 4716 4723
5. J.D. Imig, and B.D. Hammock Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat. Rev. Drug Discovery 8 2009 794 805
6. A. Iyer, D.P. Fairlie, J.B. Prins, B.D. Hammock, and L. Brown Inflammatory lipid mediators in adipocyte function and obesity Nat. Rev. Endocrinol. 6 2010 71 82
7. R.H. Ingraham, R.D. Gless, and H.Y. Lo Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions Curr. Med. Chem. 18 2011 587 603
8. A. Cronin, S. Mowbray, H. Dürk, S. Homburg, I. Fleming, B. Fisslthaler, F. Oesch, and M. Arand The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase Proc. Natl. Acad. Sci. USA 100 2003 1552 1557
9. J.W. Newman, C. Morisseau, T.R. Harris, and B.D. Hammock The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity Proc. Natl. Acad. Sci. USA 100 2003 1558 1563
10. C. Morisseau, B. Inceoglu, K. Schmelzer, H.J. Tsai, S.L. Jinks, C.M. Hegedus, and B.D. Hammock Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids J. Lipid Res. 51 2010 3481 3490
11. C. Morisseau, M.H. Goodrow, D. Dowdy, J. Zheng, J.F. Greene, J.R. Sanborn, and B.D. Hammock Potent urea and carbamate inhibitors of soluble epoxide hydrolases Proc. Natl. Acad. Sci. USA 96 1999 8849 8854
12. N. Chiamvimonvat, C.M. Ho, H.J. Tsai, and B.D. Hammock The soluble epoxide hydrolase as a pharmaceutical target for hypertension J. Cardiovasc. Pharmacol. 50 2007 225 237
13. J.D. Imig Targeting epoxides for organ damage in hypertension J. Cardiovasc. Pharmacol. 56 2010 329 335
14. J.J. Iliff, J. Jia, J. Nelson, T. Goyagi, J. Klaus, and N.J. Alkayed Epoxyeicosanoid signaling in CNS function and disease Prostaglandins Other Lipid Mediators 91 2010 68 84
15. A. Luria, C. Morisseau, H.J. Tsai, J. Yang, B. Inceoglu, B. De Taeye, S.M. Watkins, M.M. Wiest, J.B. German, and B.D. Hammock Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase Am. J. Physiol. Endocrinol. Metab. 297 2009 E375 E383
16. A.E. EnayetAllah, A. Luria, B. Luo, H.J. Tsai, P. Sura, B.D. Hammock, and D.F. Grant Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase J. Biol. Chem. 283 2008 36592 36598
17. A. Oguro, K. Sakamoto, S. Suzuki, and S. Imaoka Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth Biol. Pharm. Bull. 32 2009 1962 1967
18. B. Keserü, E. Barbosa-Sicard, R.T. Schermuly, H. Tanaka, B.D. Hammock, N. Weissmann, B. Fisslthaler, and I. Fleming Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition Cardiovasc. Res. 85 2010 232 240
19. H.H. Hou, B.D. Hammock, K.H. Su, C. Morisseau, Y.R. Kou, S. Imaoka, A. Oguro, S.K. Shyue, J.F. Zhao, and T.S. Lee N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase Cardiovasc. Res. 93 2012 120 129
20. M. Fornage, E. Boerwinkle, P.A. Doris, D. Jacobs, K. Liu, and N.D. Wong Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects Circulation 109 2004 335 339
21. K. Ohtoshi, H. Kaneto, K. Node, Y. Nakamura, T. Shiraiwa, M. Matsuhisa, and Y. Yamasaki Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients Biochem. Biophys. Res. Commun. 331 2005 347 350
22. B.D. Przybyla-Zawislak, P.K. Srivastava, J. Vásquez-Matías, H.W. Mohrenweiser, J.E. Maxwell, B.D. Hammock, J.A. Bradbury, A.E. Enayetallah, D.C. Zeldin, and D.F. Grant Polymorphisms in human soluble epoxide hydrolase Mol. Pharmacol. 64 2003 482 490
23. P.K. Srivastava, V.K. Sharma, D.S. Kalonia, and D.F. Grant Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure Arch. Biochem. Biophys. 427 2004 164 169
24. C. Fava, M. Montagnana, E. Danese, P. Almgren, B. Hedblad, G. Engström, G. Berglund, P. Minuz, and O. Melander Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes Pharmacogenet. Genomics 20 2010 94 103
25. C. Morisseau, N.H. Schebb, H. Dong, A. Ulu, P.A. Aronov, and B.D. Hammock Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids Biochem. Biophys. Res. Commun. 419 2012 796 800
26. K.L. Tran, P.A. Aronov, H. Tanaka, J.W. Newman, B.D. Hammock, and C. Morisseau Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase Biochemistry 44 2005 12179 12187
27. A.E. Enayetallah, and D.F. Grant Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis Biochem. Biophys. Res. Commun. 341 2006 254 260
28. M.I. El-Barghouthi, A.I. Saleh, A. Ghandour, R. Ghanem, and M. Zacharias Examining the potency of suggested inhibitors for the phosphatase activity of the human soluble epoxide hydrolase by molecular dynamics simulations, J. Mol. Struct. Theochem 944 2010 97 104
29. C. Morisseau, O. Merzlikin, A. Lin, G. He, W. Feng, I. Padilla, M.S. Denison, I.N. Pessah, and B.D. Hammock Toxicology in the fast lane: application of high-throughput bioassays to detect modulation of key enzymes and receptors Environ. Health Perspect. 117 2009 1867 1872
30. J.K. Beetham, T. Tian, and B.D. Hammock CDNA cloning and expression of a soluble epoxide hydrolase from human liver Arch. Biochem. Biophys. 305 1993 197 201
31. R.N. Wixtrom, M.H. Silva, and B.D. Hammock Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels Anal. Biochem. 169 1988 71 80
32. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73
33. S. Hahn, J. Achenbach, E.L. Buscató, F.M. Klingler, M. Schroeder, K. Meirer, M. Hieke, J. Heering, E. Barbosa-Sicard, F. Loehr, I. Fleming, V. Doetsch, M. Schubert-Zsilavecz, D. Steinhilber, and E. Proschak Complementary screening techniques yielded fragments that inhibit the phosphatase activity of soluble epoxide hydrolase Chem. Med. Chem. 6 2011 2146 2149
34. K. Ogino, T. Kakihara, and M. Abe Estimation of the critical micelle concentrations and aggregation numbers of sodium alkyl sulfates by capillary-type isotachophoresis Colloid Polym. Sci. 265 1987 604 612
35. Y. Tabuchi, T. Ogasawara, and K. Furuhama Mechanism of the inhibition of hog gastric H+, K(+)-ATPase by the seleno-organic compound ebselen Arzneimittelforschung 44 1994 51 54
36. K. Suzuki Anti-oxidants for therapeutic use: why are only a few drugs in clinical use? Adv. Drug Delivery Rev. 61 2009 287 289
37. K.P. Bhabak, and G. Mugesh Functional mimics of glutathione peroxidase: bioinspired synthetic antioxidants Acc. Chem. Res. 43 2010 1408 1419
38. C. Morisseau, G. Du, J.W. Newman, and B.D. Hammock Mechanism of mammalian soluble epoxide hydrolases inhibition by chalcone oxide derivatives Arch. Biochem. Biophys. 356 1998 214 228
39. E.C. Dietze, J. Stephens, J. Magdalou, D.M. Bender, M. Moyer, B. Fowler, and B.D. Hammock Inhibition of human and murine cytosolic epoxide hydrolase by group-selective reagents Comp. Biochem. Physiol. B 104 1993 299 308
40. R.L. Charles, J.R. Burgoyne, M. Mayr, S.M. Weldon, N. Hubner, H. Dong, C. Morisseau, B.D. Hammock, A. Landar, and P. Eaton Redox regulation of soluble epoxide hydrolase by 15-deoxy-delta-prostaglandin J2 controls coronary hypoxic vasodilation Circ. Res. 108 2011 324 334